Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452989 | 0.91 | ROCK2 (0.51) | ROCK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL20229984 | 0.85 | ROCK1 (0.42) | ROCK1ROCK2GSK3BDYRK1A | |
| SCHEMBL19902728 | 0.83 | ROCK1 (0.47) | ROCK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL19902496 | 0.81 | ROCK1 (0.42) | ROCK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL19902644 | 0.81 | ROCK1 (0.56) | ROCK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL20225650 | 0.77 | ROCK2 (0.52) | ROCK1ROCK2GSK3BDYRK1A | |
| SCHEMBL19902638 | 0.76 | ROCK1 (0.43) | ROCK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL17452986 | 0.75 | ROCK2 (0.50) | ROCK1KDM4ESMN1; SMN2HSD17B10ROCK2 | |
| SCHEMBL19902498 | 0.74 | ROCK2 (0.43) | ROCK1ROCK2ALDH1A1 | |
| SCHEMBL19902356 | 0.73 | CHRNA7 (0.45) | ROCK1NPC1RAB9AROCK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885NPC1 2709/4885RAB9A 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.